Novel IL-17A Blocker Continues to Impress in PsA

(MedPage Today) -- SAN DIEGO -- The triple-action investigational agent known as izokibep was highly effective against psoriatic arthritis (PsA) over 46 weeks in a new analysis of the product's first phase II trial, a researcher said here. Following...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news